Comparative effect of second-generation antipsychotic blonanserin and aripiprazole on cognitive impairment in first-episode schizophrenia: An open-label trial
- Conditions
- schizophrenia
- Registration Number
- JPRN-UMIN000010827
- Lead Sponsor
- Department of Neuropsychiatry St. Marianna University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Not provided
1) patients who had been treated with blonanserin or aripiprazole before study entry 2) comorbid central nervous system disorder 3) meeting DSM-IV-TR criteria for alcohol or other substance dependence 4) meeting DSM-IV-TR criteria for mental retardation 5) symptomatic or organic psychosis (including dementia) 6) taking tricyclic antidepressants 7) treatment with electroconvulsive therapy in the 12 weeks preceding the study 8) treatment with long-acting antipsychotics in the 12 weeks preceding the study 9) patients who are not voluntarily hospitalized 10) active expression of suicidal or homicidal ideation 11) pregnancy or breast feeding 12) inability to understand the study protocol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive function: Brief Assessment of Cognition in Schizophrenia-Japanese version (BACS-J)
- Secondary Outcome Measures
Name Time Method Psychopathology: Positive And Negative Syndrome Scale (PANSS), Clinical Global Impression- Severity (CGI-S) Functional ability: Schizophrenia Cognitive Rating Scale- Japanese version (SCoRS-J), University of California, San Diego, Performance- Based Skills Assessment (UPSA) Subjective assessments: Schizophrenia Quality of Life Scale-Japanese version (SQLS-J), Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J) Adverse effects: Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS),Weight Laboratory tests